The global actinic keratosis treatment market is anticipated to grow at a significant CAGR of 5.0% during the forecast period 2022-2028. The rising incidence and prevalence rate of actinic keratosis is expected to propel the actinic keratosis treatment market forward. For instance, the information provided by the National Center for Biotechnology Information, in February 2019, which highlighted the fact that Australia had the highest frequency of actinic keratosis, with an estimated prevalence of 37%-55% in Australian individuals over the age of 40. Whereas in UK, 15% of males and 6% of females are affected. Elderly people are also more susceptible to the development of actinic keratosis. As a result, the global actinic keratosis therapy market is being fuelled by the growing geriatric population. However, the high cost of treating actinic keratosis and the restricted treatment alternatives available may hinder the market's global expansion. 

Impact of COVID-19 Pandemic on Global Actinic Keratosis Treatment Market

The COVID-19 pandemic had a significant impact on the global actinic keratosis treatment market. Due to the imposition of the lockdown, people were not able to go for proper diagnosis and treatment of actinic keratosis. As a result, the cases became severe and turned into squamous cell carcinoma, a skin cancer. Additionally, the lack of availability of diagnosis and health workers involvement majorly in the cause of the spread of the disease impacted the market. This caused a decline in the growth of the global actinic keratosis treatment market. 

Segmental Outlook

The global actinic keratosis treatment market is segmented based on type and end-user. Based on the type, the market is segmented into medication and therapy. Based on medication, the market is sub-segmented into fluorouracil, imiquimod, Ingersol mebutate, and others. Based on therapy, the market is sub-segmented into photodynamic therapy, laser surgery, and others. Based on end-user, the market is sub-segmented into hospitals & oncology centers, and dermatology clinics. 

Global Actinic Keratosis Treatment Market Share by Type, 2021 (%) 

The Medication Segment is Anticipated to Hold a Prominent Share in the Global Actinic Keratosis Treatment Market

The medication segment is anticipated to hold the significant share in the market due to the easy availability of products, effective target specificity, and decreased risk of scarring. There is a high risk of getting a permanent scar after the therapy treatment, due to which medication is the preferred type by the people. Fluorouracil, imiquimod, diclofenac, ingenol mebutate, and combination treatment with medicines are some of the treatments approved by the US Food and Drug Administration (FDA) for the treatment of actinic keratoses. Furthermore, in the topical pharmaceuticals category, promising pipeline drugs and the growing use of combination treatment are the main driving forces that contribute to the growth of the market.

Regional Outlooks

The global actinic keratosis treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others), and the Rest of the World (the Middle East & Africa, and Latin America).  Some factors that are boosting the market growth in the Asia-Pacific region are, improving healthcare infrastructure, and growing R&D funding for new therapies in the region. Additionally, the increasing geriatric population along with the existence of a large number of players providing effective offerings are some other main factor that is providing support to the growth of the market in the region.

Global Actinic Keratosis Treatment Market Growth, by Region 2022-2028 

The North America Region is Estimated to Hold the Major Share in the Global Actinic Keratosis Treatment Market

The North American region is expected to hold a significant share in the global actinic keratosis treatment market due to rising awareness regarding actinic keratosis and the relating risk of developing squamous cell carcinoma. Additionally, the people are going for a timely diagnosis of the disease, in order to prevent themselves from getting skin cancer. For instance, in July 2021, according to the National Centre for Biotechnology Information, the prevalence of actinic keratosis is higher where fair skin type individuals are predominant and high exposure to UV radiation occurs. In the US, 11.5%-26% of Caucasians above 40 years of age are exposed to actinic keratosis.

Market Players Outlook

3M Co., Alma Lasers Inc., Almirall SA, Bausch Health Companies Inc., and Biofrontera AG, among others, are some of the leading participants in the global actinic keratosis treatment market industry. To increase market share around the globe, these companies are using a variety of techniques, including mergers and acquisitions, product launches, geographic expansion and collaboration, and partnership. For instance, in February 2021, Eucerin (a subsidiary of Beiersdorf AG) launched Actinic Control SPF100, a new and effective sun protection product that prevents actinic keratosis and nonmelanoma skin cancer while also providing skin that is sensitive to the sun with effective protection from sun-induced skin damage. As such, it also serves as an adjuvant treatment for patients already affected by actinic keratosis.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global actinic keratosis treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market